Novartis expands cancer immunotherapy research program with acquisition of CoStim »

[at noodls] – Acquisition adds novel immune modulating targets and technology to accelerate Novartis cancer immunotherapy program Novartis and University of Pennsylvania CAR immunotherapy research combined with CoStim … more

View todays social media effects on NVS

View the latest stocks trending across Twitter. Click to view dashboard

See who Novartis is hiring next, click here to view